Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group
- PMID: 11089822
- DOI: 10.1016/s0140-6736(00)03157-3
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group
Abstract
Background: Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on trial.
Methods: After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double-blind period of 2 months. Patients then received stiripentol in an open fashion. Responders were defined as having more than 50% reduction in the frequency of clonic (or tonic-clonic) seizures during the second month of the double-blind period compared with baseline.
Findings: 15 (71%) patients were responders on stiripentol (including nine free of clonic or tonic-clonic seizures), whereas there was only one (5%) on placebo (none were seizure free; stiripentol 95% CI 52.1-90.7 vs placebo 0-14.6). The 95% CI of the difference was 42.2-85.7. Percentage of change from baseline was higher on stiripentol (-69%) than on placebo (+7%), p<0.0001. 21 patients on stiripentol had moderate side-effects (drowsiness, loss of appetite) compared with eight on placebo, but side-effects disappeared when the dose of comedication was decreased in 12 of the 21 cases.
Interpretation: This controlled trial shows the antiepileptic efficacy, of add-on stiripentol in children with SMEI. The results also provide good reason to focus studies on a specific epilepsy syndrome-a small sample of patients is sufficient to show the efficacy that might have been missed in a heterogeneous population.
Comment in
-
Epilepsy syndrome-specific anti-epileptic drug therapy for children.Lancet. 2000 Nov 11;356(9242):1623-4. doi: 10.1016/S0140-6736(00)03151-2. Lancet. 2000. PMID: 11089816 Clinical Trial. No abstract available.
Similar articles
-
Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).CNS Drugs. 2012 Nov;26(11):993-1001. doi: 10.1007/s40263-012-0004-3. CNS Drugs. 2012. PMID: 23018548 Review.
-
Stiripentol: new preparation. Severe myoclonic epilepsy of infancy: promising.Prescrire Int. 2005 Apr;14(76):57-9. Prescrire Int. 2005. PMID: 15875342
-
Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.Epilepsy Res. 2014 May;108(4):725-31. doi: 10.1016/j.eplepsyres.2014.02.008. Epub 2014 Feb 19. Epilepsy Res. 2014. PMID: 24630050 Clinical Trial.
-
Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.Epilepsy Res. 2015 Jul;113:90-7. doi: 10.1016/j.eplepsyres.2015.03.012. Epub 2015 Apr 6. Epilepsy Res. 2015. PMID: 25986195 Clinical Trial.
-
Stiripentol: A Review in Dravet Syndrome.Drugs. 2019 Nov;79(16):1785-1796. doi: 10.1007/s40265-019-01204-y. Drugs. 2019. PMID: 31617141 Review.
Cited by
-
Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free Periods.Neurol Ther. 2024 Jun;13(3):869-884. doi: 10.1007/s40120-024-00623-8. Epub 2024 May 9. Neurol Ther. 2024. PMID: 38722572 Free PMC article.
-
Established and emerging GABAA receptor pharmacotherapy for epilepsy.Front Pharmacol. 2024 Feb 21;15:1341472. doi: 10.3389/fphar.2024.1341472. eCollection 2024. Front Pharmacol. 2024. PMID: 38449810 Free PMC article. Review.
-
An Update on Stiripentol Mechanisms of Action: A Narrative Review.Adv Ther. 2024 Apr;41(4):1351-1371. doi: 10.1007/s12325-024-02813-0. Epub 2024 Mar 5. Adv Ther. 2024. PMID: 38443647 Free PMC article. Review.
-
Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression.Nat Commun. 2024 Mar 5;15(1):1987. doi: 10.1038/s41467-024-46193-z. Nat Commun. 2024. PMID: 38443336 Free PMC article.
-
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.Epilepsia Open. 2024 Apr;9(2):689-703. doi: 10.1002/epi4.12923. Epub 2024 Mar 1. Epilepsia Open. 2024. PMID: 38427284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical